Charles C. Bailey

This paper describes a trimeric inhibitor, S22, that stabilizes the SARS-CoV-2 spike protein in a closed conformation, preventing ACE2 binding and viral entry.

This study demonstrates that non-antibody protein biologics can undergo affinity maturation in vivo, leading to improved binding affinity and neutralization potency against HIV-1.

This study demonstrates that CRISPR-edited murine B cells expressing human antibodies can undergo affinity maturation, generating potent neutralizing antibodies against HIV-1 and SARS-CoV-2.